ART Receives $500,000 From Government of Canada to Pursue Commercialization Activities in North America

09-Jul-2009 - Canada

ART Advanced Research Technologies Inc. reported that it has been awarded $500,000 in repayable funding by the Government of Canada for the commercialization of its Optix® MX3 and SoftScan® optical molecular imaging products in North America. The Honourable Christian Paradis, Minister of Public Works and Government services Canada and Minister responsible for the Montréal region, announced the contribution on behalf of the federal government at a press conference held at ART's headquarters.

ART's two lead products-SoftScan and Optix-are based on a technology that uses light to measure physiological changes in living tissue, indicating the presence of anomalies, tumours, or lesions. In clinical settings, the SoftScan system for breast imaging is demonstrating its importance as a valuable tool for clinicians in the diagnosis and treatment monitoring of breast cancer. Oncologists are able to see rapidly if a course of treatment is working and then adjust or interrupt treatment. ART's other key imaging device, the Optix molecular imaging system, is designed to visualize and characterize molecular events in small animals at the preclinical study phases of new drugs. A pre-commercial launch of the new generation of the system, called Optix MX3, was held last May in Europe.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances